Despite no receptor expressed on osteoblast, GLP-1 administration in several preclinical models of bone disorders demonstrated a potential for enhancing collagen post-processing, suggesting that the actions of GLP-1 are extraskeletal (12, 17, 18, 39). Here, GCG is linked to bone disorder.